|
|
 Previous Article | Table of Contents | Next Article 
Trisomy 13: a new recurring chromosome abnormality in acute leukemia
H Dohner, DC Arthur, ED Ball, RE Sobol, FR Davey, D Lawrence, L Gordon, SR Patil, RB Surana and JR Testa
Cancer and Leukemia Group B, Boston, MA.
A new recurring chromosome abnormality was identified in 8 of 621
consecutive successfully karyotyped adults with de novo acute leukemia.
These eight patients had trisomy 13 as the sole cytogenetic abnormality. On
central morphologic review, five cases were classified as subtypes of acute
myeloid leukemia, one as acute mixed lymphoid and myeloid leukemia, one as
acute lymphoid leukemia, and one as acute undifferentiated leukemia. Blasts
of all eight cases expressed one or more myeloid differentiation antigens.
Three also expressed T-lineage- associated antigens; however, none of these
had rearrangement of the T- cell receptor beta, gamma, or delta genes. Four
of six cases tested were TdT positive. All eight patients with trisomy 13
were treated with intensive induction chemotherapy; only three entered a
short-lived complete remission. Survival of patients with trisomy 13 ranged
from 0.5 to 14.7 months, and was significantly shorter than that of the
remaining patients (median 9.5 v 16.2 months, P = .007). We conclude that
trisomy 13 is a rare, recurring clonal chromosome abnormality in acute
leukemia associated with a poor prognosis. Malignant transformation of an
immature hematopoietic precursor cell is suggested by the expression of
antigens characteristic of both the myeloid and lymphoid lineage, the high
incidence of TdT positivity, and the morphologic heterogeneity in these
leukemias.
Volume 76,
Issue 8,
pp. 1614-1621,
10/15/1990
Copyright © 1990 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
F. Dicker, C. Haferlach, W. Kern, T. Haferlach, and S. Schnittger
Trisomy 13 is strongly associated with AML1/RUNX1 mutations and increased FLT3 expression in acute myeloid leukemia
Blood,
August 15, 2007;
110(4):
1308 - 1316.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. P.G. Silva, A. Lind, G. Brouwer-Mandema, P. J.M. Valk, and M. Giphart-Gassler
Trisomy 13 correlates with RUNX1 mutation and increased FLT3 expression in AML-M0 patients
Haematologica,
August 1, 2007;
92(8):
1123 - 1126.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. D. Radmacher, G. Marcucci, A. S. Ruppert, K. Mrozek, S. P. Whitman, J. W. Vardiman, P. Paschka, T. Vukosavljevic, C. D. Baldus, J. E. Kolitz, et al.
Independent confirmation of a prognostic gene-expression signature in adult acute myeloid leukemia with a normal karyotype: a Cancer and Leukemia Group B study
Blood,
September 1, 2006;
108(5):
1677 - 1683.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. S. Farag, K. J. Archer, K. Mrozek, A. S. Ruppert, A. J. Carroll, J. W. Vardiman, M. J. Pettenati, M. R. Baer, M. B. Qumsiyeh, P. R. Koduru, et al.
Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461
Blood,
July 1, 2006;
108(1):
63 - 73.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. D. Bloomfield, K. Mrozek, and M. A. Caligiuri
Cancer and Leukemia Group B Leukemia Correlative Science Committee: Major Accomplishments and Future Directions.
Clin. Cancer Res.,
June 1, 2006;
12(11):
3564s - 3571s.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Compton
The cancer and leukemia group B pathology committee at 50.
Clin. Cancer Res.,
June 1, 2006;
12(11):
3617s - 3621s.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Marcucci, C. D. Baldus, A. S. Ruppert, M. D. Radmacher, K. Mrozek, S. P. Whitman, J. E. Kolitz, C. G. Edwards, J. W. Vardiman, B. L. Powell, et al.
Overexpression of the ETS-Related Gene, ERG, Predicts a Worse Outcome in Acute Myeloid Leukemia With Normal Karyotype: A Cancer and Leukemia Group B Study
J. Clin. Oncol.,
December 20, 2005;
23(36):
9234 - 9242.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Marcucci, K. Mrozek, A. S. Ruppert, K. Maharry, J. E. Kolitz, J. O. Moore, R. J. Mayer, M. J. Pettenati, B. L. Powell, C. G. Edwards, et al.
Prognostic Factors and Outcome of Core Binding Factor Acute Myeloid Leukemia Patients With t(8;21) Differ From Those of Patients With inv(16): A Cancer and Leukemia Group B Study
J. Clin. Oncol.,
August 20, 2005;
23(24):
5705 - 5717.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Marcucci, K. Mrozek, A. S. Ruppert, K. J. Archer, M. J. Pettenati, N. A. Heerema, A. J. Carroll, P. R.K. Koduru, J. E. Kolitz, L. J. Sterling, et al.
Abnormal Cytogenetics at Date of Morphologic Complete Remission Predicts Short Overall and Disease-Free Survival, and Higher Relapse Rate in Adult Acute Myeloid Leukemia: Results From Cancer and Leukemia Group B Study 8461
J. Clin. Oncol.,
June 15, 2004;
22(12):
2410 - 2418.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. C. Byrd, K. Mrozek, R. K. Dodge, A. J. Carroll, C. G. Edwards, D. C. Arthur, M. J. Pettenati, S. R. Patil, K. W. Rao, M. S. Watson, et al.
Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)
Blood,
December 15, 2002;
100(13):
4325 - 4336.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Mrozek, T. W. Prior, C. Edwards, G. Marcucci, A. J. Carroll, P. J. Snyder, P. R.K. Koduru, K. S. Theil, M. J. Pettenati, K. J. Archer, et al.
Comparison of Cytogenetic and Molecular Genetic Detection of t(8;21) and inv(16) in a Prospective Series of Adults With De Novo Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study
J. Clin. Oncol.,
May 1, 2001;
19(9):
2482 - 2492.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Mrozek, K. Heinonen, D. Lawrence, A. J. Carroll, P. R.K. Koduru, K. W. Rao, M. P. Strout, R. E. Hutchison, J. O. Moore, R. J. Mayer, et al.
Adult Patients With De Novo Acute Myeloid Leukemia and t(9; 11)(p22; q23) Have a Superior Outcome to Patients With Other Translocations Involving Band 11q23: A Cancer and Leukemia Group B Study
Blood,
December 1, 1997;
90(11):
4532 - 4538.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Venditti, G. Del Poeta, F. Buccisano, A. Tamburini, M. C. Cox, R. Stasi, A. Bruno, G. Aronica, L. Maffei, G. Suppo, et al.
Minimally Differentiated Acute Myeloid Leukemia (AML-M0): Comparison of 25 Cases With Other French-American-British Subtypes
Blood,
January 15, 1997;
89(2):
621 - 629.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
